India’s drug-resistance problem is bigger than antibiotic overuse

Source: The post “India’s drug-resistance problem is bigger than antibiotic overuse” has been created based on “India’s drug-resistance problem is bigger than antibiotic overuse” published in “Indian Express” on 03rd September 2026.

UPSC Syllabus: GS-3-Science and technology

Context: Antimicrobial resistance (AMR) occurs when bacteria develop resistance to antibiotics, making infections more difficult and costly to treat. A recent ICMR study across 20 tertiary-care hospitals, covering 1,59,336 hospitalised patients between April 2022 and April 2025, highlights the serious mortality and economic burden of carbapenem-resistant Gram-negative infections.

Why is the situation alarming?

1. Higher mortality: Carbapenem-resistant infections were associated with a 16–43% higher relative risk of death across E. coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa.
2. High mortality in bloodstream infections: Mortality among resistant bloodstream infections ranged from around 39% in resistant E. coli to 51% in resistant A. baumannii.
3. High resistance in tertiary hospitals: More than 61% of Gram-negative infections in the study were carbapenem-resistant, although this figure should not be treated as representative of the general community because these hospitals largely handle referred and critically ill patients.
4. Higher treatment costs: Antibiotic costs for resistant infections were 1.1–2 times higher, while the actual economic burden is likely to be much greater after including ICU care, diagnostics, procedures, supportive care and hospital charges.

Factors driving AMR beyond antibiotic overuse

1. Healthcare-associated transmission: More than 85% of bloodstream infections in the study were classified as healthcare-associated, highlighting the role of transmission within hospitals.
2. Gaps in infection prevention: Inadequate hand hygiene, environmental cleaning and surgical infection prevention can facilitate the spread of resistant organisms.
3. Invasive medical devices: Catheters and other invasive devices increase infection risk, particularly when they are not removed at the earliest appropriate opportunity.
4. Recent surgery and critical illness: Surgical procedures, severe illness and multiple comorbidities can increase vulnerability to resistant infections.
5. Delayed diagnosis: Late recognition of infection delays appropriate treatment and allows patients to deteriorate.
6. Inadequate or delayed therapy: Resistance may not be identified quickly enough, leaving clinicians with fewer effective treatment options.
7. Antibiotic selection pressure: Excessive or inappropriate antibiotic exposure promotes the emergence and spread of resistant bacteria.

Way forward

1. Strengthen infection prevention and control: Hospitals must prioritise hand hygiene, environmental cleaning, device-associated infection prevention, surgical infection prevention and surveillance of healthcare-associated infections.
2. Improve diagnostics: Faster and more accurate diagnostics should help distinguish bacterial from non-bacterial illness and identify resistance at an early stage.
3. Ensure antimicrobial stewardship: Antibiotics should be used at the narrowest effective spectrum and for the shortest appropriate duration, rather than routinely escalating to stronger drugs.
4. Integrate AMR surveillance: India should move beyond isolate-based surveillance towards patient-level surveillance linking laboratory results with treatment and mortality outcomes.
5. Ensure responsible access to newer antimicrobials: Effective newer drugs should remain available for patients who genuinely need them while being protected through appropriate stewardship.
6. Use evidence cautiously: Drugs such as ceftazidime-avibactam showed beneficial associations in some resistant E. coli and Klebsiella infections, but observational evidence cannot establish universal superiority. Treatment should therefore be guided by diagnostics and resistance mechanisms.

Conclusion: AMR is not merely an antibiotic-prescribing problem; it is also an infection-prevention, diagnosis, transmission and healthcare-system problem. Antibiotics cannot compensate for failures in infection prevention. Therefore, India needs an integrated strategy combining prevention, early diagnosis, surveillance, antimicrobial stewardship and responsible access to effective newer treatments.

Question: Antimicrobial resistance (AMR) cannot be addressed merely by controlling antibiotic overuse. Discuss the factors driving drug-resistant infections in India and suggest an integrated approach to tackle the problem.

Source: Indian Express